Randomized controlled trial comparing 7-day fexuprazan-based and 14-day rabeprazole-based triple therapies for Helicobacter pylori eradication.

In 30 seconds

This randomized controlled trial evaluated the efficacy and safety of a 7-day fexuprazan-based triple therapy versus a 14-day rabeprazole-based regimen for Helicobacter pylori eradication in Korean patients. The study found comparable eradication rates of 80.00% for fexuprazan and 82.05% for rabeprazole, with no significant differences in safety profiles.

Key findings

• Eradication rates were 80.00% for fexuprazan and 82.05% for rabeprazole in the full analysis set.
• In the per-protocol set, eradication rates were 83.78% for fexuprazan and 88.89% for rabeprazole.
• The overall incidence of treatment-emergent adverse events was 70.00% in the fexuprazan group and 66.67% in the rabeprazole group.

Why it matters

The findings suggest that a shorter, 7-day fexuprazan-based therapy is as effective as the standard 14-day rabeprazole-based therapy for H. pylori eradication, potentially improving patient adherence and treatment outcomes.